MapLight Therapeutics (MPLT US): Synthetic Expert Call Transcript (21 Sep 2026)
The failure of MapLight’s once-daily (QD) dosing regimen for ML-007C-MA in the Phase 2 ZEPHYR trial is a severe commercial blow. By failing to...
98 Views
IPO Databook: MapLight Therapeutics (MPLT US) - Sep 2026
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders. This...
98 Views
Primer: MapLight Therapeutics (MPLT US) - Aug 2026
MapLight Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline targeting significant unmet needs in central...
102 Views
MapLight Therapeutics Inc. (MPLT): Oversubscribed Neuroscience IPO Launches with a Bright Start
​MapLight Therapeutics Inc. (MPLT) sees strong investor demand, pricing IPO above range and opening with 11.7% gain on first trade.
735 Views
Maplight Therapeutics (MPLT): Clubby Biotech Deal Anticipated as IPO Market Pushes Ahead
​MapLight Therapeutics secures significant anchor order and private placement, poised for success with strong investor support and scientific...
962 Views